Novigenix is committed to providing a new understanding of the human host response against cancer and its response to therapy. The Company was founded on the vision that Immuno-Transcriptomics will bring unprecedented advances in diagnosing and treating cancer patients, leading to significant improvement in medical outcomes. Novigenix’s unique Immuno-Transcriptomics technology enables an accelerated identification of disease specific mRNA signatures of immune cells, which combined with machine learning and predictive algorithms, can provide new insights into onset and progression of disease. The Company has established a valuable multi-ethnical biobank of cancer patients and has launched its first Immuno-Transcriptomic molecular diagnostic blood test Colox® on the Swiss market for the early detection of colon cancer.